Business
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent Highlights Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidatesCash position of approximately $74.7 million as of March 31, 2026 expected to fund current operat
About this update from Instil Bio, Inc.
[{"type":"image","alt":"Instil Bio","displaySize":"","headline":null,"caption":"Instil Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lyBTP_8CzLdFqw7HVrNzUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b","width":300,"height":157},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/lyBTP_8CzLdFqw7HVrNzUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b","width":300,"height":157}},"lazy":false},{"type":"text","content":"DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update.","length":258,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"text","content":"“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said Bronson Crouch, Chief Executive Officer, Instil Bio. “We are actively evaluating a range of acquisition and in-licensing opportunities, with a focus on assets that align with our capabilities and offer the potential to create long-term value. With a strong balance sheet, we are well positioned to act with discipline and flexibility as we work to build a focused, high-quality pipeline and advance new treatment options for patients.”","length":556,"tagName":"p"},{"type":"text","content":"There can be no assurance that any transaction will result from these efforts, nor as to the timing of any such outcome. Instil does not intend to provide further update...